MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
MVP - MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.15
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.15
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.54
26 Apr |
-0.020 OPEN $0.55 |
-3.57% HIGH $0.57 |
74,207 LOW $0.54 |
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
Last ex-div: 05/03 - ex-div 2c (franking 100%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -6.7 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 32.3 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 94.2 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -16.5 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -17.35 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -8.09 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -7.83 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -5.32 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -8.09 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -28.16 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -18.3 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 3 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 9 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 25 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 0.82 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 7.7 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 23.70 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 35 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 18 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
MVP STOCK CHART
FNArena News on MVP
1 |
FNArena Corporate Results Monitor – 01-09-2023Sep 01 2023 - Australia |
2 |
Australian Broker Call *Extra* Edition – Mar 08, 2023Mar 08 2023 - Daily Market Reports |
3 |
Australian Broker Call *Extra* Edition – Nov 01, 2022Nov 01 2022 - Daily Market Reports |
4 |
Australian Broker Call *Extra* Edition – Oct 11, 2022Oct 11 2022 - Daily Market Reports |
5 |
Australian Broker Call *Extra* Edition – Sep 06, 2022Sep 06 2022 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
2 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
3 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
4 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
5 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
6 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
7 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
8 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
9 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |